TuHURA Biosciences, Inc./NV (HURA) Form 10-Q — May 15, 2026
TuHURA Biosciences reported a net loss of $7.5 million for the three months ended March 31, 2026, driven by $5.2 million in R&D expenses and $2.3 million in G&A. The company ended the quarter with $6.3 million in cash and an accumulated deficit of $148.7 million. In subsequent events, TuHURA entered into a $50 million revolving credit facility with Parkview Holdings One LLC, an affiliate of its largest shareholder. The facility bears 12% interest, is secured by substantially all assets, and includes a royalty agreement on future IFx-2.0 sales.
Key figures
- Total Assets
- 29704779
- Cash Position
- 6298127
- Shares Outstanding
- 63578528
- Ga Expenses
- 2297358
- Rd Expenses
- 5232541
- Atm Capacity
- 50000000
- Credit Facility Capacity
- 50000000
Price after filing
Close on the filing date to close N calendar days later (from $2.51). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.